Filing Details

Accession Number:
0001610717-23-000098
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-06 19:23:22
Reporting Period:
2023-06-01
Accepted Time:
2023-06-06 19:23:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650648 4D Molecular Therapeutics Inc. FMDT Biological Products, (No Disgnostic Substances) (2836) 473506994
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1920738 Scott Bizily C/O 4D Molecular Therapeutics, Inc.
5858 Horton Street #455
Emeryville CA 94608
Chief Legal And Hr Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-01 1,875 $6.49 3,984 No 4 M Direct
Common Stock Disposition 2023-06-01 2,247 $18.31 1,737 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-06-01 1,875 $0.00 1,875 $6.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,375 2032-06-17 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1.
  2. The transaction was executed in multiple trades in prices ranging from $17.95 to $18.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.